Abstract
The focal dystonia benign essential blepharospasm (BEB) affects as many as 40,000 individuals in the United States. This dystonia is characterized by trigeminal hyperexcitability, photophobia, and most disabling of the symptoms, involuntary spasms of lid closure that can produce functional blindness. Like many focal dystonias, BEB appears to develop from the interaction between a predisposing condition and an environmental trigger. The primary treatment for blepharospasm is to weaken the eyelid-closing orbicularis oculi muscle to reduce lid spasms. There are several animal models of blepharospasm that recreate the spasms of lid closure in order to investigate pharmacological treatments to prevent spasms of lid closure. One animal model attempts to mimic the predisposing condition and environmental trigger that give rise to BEB. This model indicates that abnormal interactions among trigeminal blink circuits, basal ganglia, and the cerebellum are the neural basis for BEB.
Keywords: Basal ganglia, blepharospasm, blink, cerebellum, motor adaptation, trigeminal
Current Neuropharmacology
Title:Animal Models for Investigating Benign Essential Blepharospasm
Volume: 11 Issue: 1
Author(s): Craig Evinger
Affiliation:
Keywords: Basal ganglia, blepharospasm, blink, cerebellum, motor adaptation, trigeminal
Abstract: The focal dystonia benign essential blepharospasm (BEB) affects as many as 40,000 individuals in the United States. This dystonia is characterized by trigeminal hyperexcitability, photophobia, and most disabling of the symptoms, involuntary spasms of lid closure that can produce functional blindness. Like many focal dystonias, BEB appears to develop from the interaction between a predisposing condition and an environmental trigger. The primary treatment for blepharospasm is to weaken the eyelid-closing orbicularis oculi muscle to reduce lid spasms. There are several animal models of blepharospasm that recreate the spasms of lid closure in order to investigate pharmacological treatments to prevent spasms of lid closure. One animal model attempts to mimic the predisposing condition and environmental trigger that give rise to BEB. This model indicates that abnormal interactions among trigeminal blink circuits, basal ganglia, and the cerebellum are the neural basis for BEB.
Export Options
About this article
Cite this article as:
Evinger Craig, Animal Models for Investigating Benign Essential Blepharospasm, Current Neuropharmacology 2013; 11 (1) . https://dx.doi.org/10.2174/1570159X11311010008
DOI https://dx.doi.org/10.2174/1570159X11311010008 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Mucoadhesive Polymers for Oral Transmucosal Drug Delivery: A Review
Current Pharmaceutical Design Lipids as Key Players in Alzheimer Disease - Alterations in Metabolism and Genetics
Current Alzheimer Research Voltage-Gated Sodium Channels as Therapeutic Targets for Treatment of Painful Diabetic Neuropathy
Mini-Reviews in Medicinal Chemistry Synthetic Glucocorticoids: Antenatal Administration and Long-term Implications
Current Pharmaceutical Design Sleep Disturbances Due to Pulmonary Medications
Current Respiratory Medicine Reviews Nanochannel Systems for Personalized Therapy and Laboratory Diagnostics
Current Pharmaceutical Biotechnology The Role of Ionotropic Glutamate Receptors in Childhood Neurodevelopmental Disorders: Autism Spectrum Disorders and Fragile X Syndrome
Current Neuropharmacology Innovative In Silico Approaches to Address Avian Flu Using Grid Technology
Infectious Disorders - Drug Targets Recent Progress in the Development of Agonists and Antagonists for Melatonin Receptors
Current Medicinal Chemistry Eph/Ephrin Signalling and Function in Oncogenesis: Lessons from Embryonic Development
Current Cancer Drug Targets The Mechanisms and Quantification of the Selective Permeability in Transport Across Biological Barriers: the Example of Kyotorphin
Mini-Reviews in Medicinal Chemistry FK506-Binding Proteins and Their Diverse Functions
Current Molecular Pharmacology Aquaporin and Vascular Diseases
Current Neuropharmacology New Molecular Avenues in Parkinson ’ s Disease Therapy
Current Topics in Medicinal Chemistry Recent Updates on Development of Drug Molecules for Human African Trypanosomiasis
Current Topics in Medicinal Chemistry The Phosphoinositide 3-Kinase Pathway in Human Cancer: Genetic Alterations and Therapeutic Implications
Current Genomics Long Term Ketamine and Ketamine Plus Alcohol Toxicity - What can we Learn from Animal Models?
Mini-Reviews in Medicinal Chemistry 5-HT3 Receptors
Current Drug Targets - CNS & Neurological Disorders Old and New Antiepileptic Drugs for the Treatment of Idiopathic Generalized Epilepsies
Current Clinical Pharmacology Deep Brain Stimulation: A New Treatment in Mood and Anxiety Disorders
CNS & Neurological Disorders - Drug Targets